This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Richard D. Hurt, MD; Kenneth P. Offord, MS
Mayo Clinic Rochester, Minn

JAMA. 1994;272(1):32.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Lahad's letter discusses the possible role that univariate disparities in various baseline factors might have in explaining the difference in smoking cessation rates in our double-blind, placebo-controlled, randomized trial. Adjustment for such factors is more critical in epidemiologic retrospective, nonrandomized studies where various biases may distort the findings.

Two points are noteworthy. First, our results showing the efficacy of transdermal nicotine replacement therapy are consistent with other randomized trials where, in general, active treatment results in a doubling of the smoking cessation rate.^1-3 Second, using logistic regression, we reanalyzed the 8-week and 1-year cessation rates, adjusting for the six baseline variables mentioned by Dr Lahad (employed, depressed or "down," previously treated for depression, pack-years of cigarette smoking, serum cotinine level, and baseline withdrawal symptom score). Assignment to active patch treatment was still a significant predictor of cessation adjustment for these after 8 weeks (two-tail P<.001) . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?